Supporting A Clinical-Stage Oncology Company In Manufacturing The RSM For Treating A Rare Tumour

A clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers had two product candidates under development and needed a partner to manufacture the regulatory starting material (RSM-II) for two final API candidates.

Syngene synthesized the RSM and all the undesired isomers of the RSM, including specific impurities. Further, before scale-up, the Syngene team reduced the steps required for synthesis to half by implementing alternate strategies to minimize the operation time.

Review the results of the study and examine how an optimized RSM manufacturing process helped deliver safe, effective treatment on an accelerated timeline.